e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): May 15, 2009
Valeant Pharmaceuticals International
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
1-11397
|
|
33-0628076 |
(State or other jurisdiction of
|
|
(Commission File Number)
|
|
(I.R.S Employer |
incorporation or organization)
|
|
|
|
Identification No.) |
One Enterprise
Aliso Viejo, California 92656
(Address of principal executive offices) (Zip Code)
(949) 461-6000
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
Item 3.03 Material Modification to Rights of Security Holders.
(a) On May 15, 2009, Valeant Pharmaceuticals International, a Delaware corporation (the
Company), and American Stock Transfer & Trust Company, as Rights Agent entered into Amendment No.
3 (Amendment No. 3) to the Rights Agreement by and between the Company and American Stock
Transfer & Trust Company, as Rights Agent, dated as of November 2, 1994, as amended by Amendment
No. 1 to the Rights Agreement, dated as of October 5, 2004 (Amendment No. 1) and Amendment No. 2
to the Rights Agreement, dated as of June 5, 2008 (Amendment No. 2, and as so amended, the
Rights Agreement).
Amendment No. 3 amends the Rights Agreement to exempt an Institutional Investor owning less
than 30% of the Companys then-outstanding Common Stock from being an Acquiring Person under the
Rights Agreement. Except to the extent expressly modified by Amendment No. 3, the Rights
Agreement, as previously amended by Amendments No. 1 and No. 2, remains in full force and effect in
all respects.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Date: May 15, 2009 |
VALEANT PHARMACEUTICALS
INTERNATIONAL
|
|
|
By: |
/s/ Steve T. Min
|
|
|
|
Name: |
Steve T. Min |
|
|
|
Title: |
Executive Vice President
and General Counsel |
|
3